THYROCARE · Healthcare · Diagnostics & Research
Composite scorecard: 71/100 — Quality 98 · Valuation 15 · Momentum 100
| Share price | ₹555.50 |
| Market cap | ₹8,208 Cr |
| P/E ratio | 50.5 |
| P/B ratio | 15.3 |
| ROE | 55.7% |
| ROCE | 33.8% |
| Dividend yield | 3.17% |
| Book value | ₹33.60 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹829 Cr | ₹163 Cr | 32.0% |
| 2025 | ₹687 Cr | ₹91 Cr | 28.0% |
| 2024 | ₹572 Cr | ₹69 Cr | 24.0% |
| 2023 | ₹527 Cr | ₹64 Cr | 23.0% |
| 2022 | ₹589 Cr | ₹176 Cr | 40.0% |
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company wa